Abstract 668P
Background
4-1BB-targeted therapies have the potential to address an important need in immuno-oncology, providing clinical benefits in checkpoint inhibitor refractory patients. ALG.APV-527 is a bispecific antibody targeting co-stimulatory receptor 4-1BB and oncofetal antigen 5T4, expressed on multiple solid tumor types. Based on its profile, 5T4 is an attractive tumor-associated antigen for bispecific therapy, enabling targeted delivery of an immune agonist.
Methods
The Phase I study is a first-in-human, open-label, multicenter trial consisting of six cohorts (0.1-15 mg/kg) in a 3+3 dose escalation of ALG.APV-527 monotherapy, administered intravenously Q2W, in adult patients with advanced solid tumors. Eligibility is limited to patients with tumor types identified as likely to express 5T4 antigen. Key endpoints include safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity of ALG.APV-527.
Results
ALG.APV-527 has been well tolerated; a total of 14 patients experienced 73 treatment-related adverse events. Most events were mild to moderate and manageable in the clinic; G1=30 (41%), G2=32, (44%), G3=8 (11%), G4=3 (4%), G5=0. One patient experienced a G4 dose limiting toxicity of febrile neutropenia. An MTD has yet to be determined. Exposure has shown to be associated with serum protein changes relevant to ALG.APV-527 activity. Two heavily pretreated breast cancer patients experienced prolonged stable disease of over 7 months and 11 months (escalated to a higher dose level without any added adverse events) and remains on study.
Conclusions
ALG.APV-527 demonstrates good tolerability, safety, biological activity, and prolonged SD among two heavily pretreated breast cancer patients. Dose escalation is ongoing to identify MTD and recommended Phase 2 dose.
Clinical trial identification
NCT05934539.
Editorial acknowledgement
Legal entity responsible for the study
Aptevo Therapeutics and Alligator Bioscience.
Funding
Aptevo Therapeutics and Alligator Bioscience.
Disclosure
T. Marron: Financial Interests, Personal, Advisory Board: Regeneron, AstraZeneca, Genentech, G1 Therapeutics, Arcus, Glenmark, Merck, NGMBio, Glenmark, AbbVie, Fate; Financial Interests, Institutional, Coordinating PI: Regeneron, Genentech, Boehringer Ingelheim, Merck. S. Rosen: Financial Interests, Personal, Stocks/Shares, Stocks: Lilly, Pfizer, BMS, Amgen. J. Powderly II: Financial Interests, Personal and Institutional, Member of Board of Directors: BioCytics ; Financial Interests, Personal, Writing Engagement: Aavocyte; Other, Personal, Advisory Role: Boxer Capital; Financial Interests, Personal, Ownership Interest: Carolina Biooncology Institute, Biocytics, Carolina Biooncology Institute, Biocytics; Financial Interests, Personal, Other: Aavocyte; Non-Financial Interests, Personal and Institutional, Local PI: AbbVie, Alkermes, Apollo, Apros, Arcus, Astellas, AstraZeneca, Medimune, Altreca, BioNTech, BJ Biosciences, Bristol Myers Squibb, Calico Life Sciences, Conjupro Biotherapeutics, Corbus, Cullinan, CytoMx, Fate Therapeutics, FBD Biologics, FLX Bio, Genentech/Roche, Glenmark, I-MAB Pharma, Immune Onc, InCyte, Jounce Therapeutics, Macrogenics, McBrace, Merck, Molecular Templates, Multitude, NexCure, Nuvation, Repertoire, Revolution Medicines, Sairopa, Seattle Genetics, Sequenom, Tempest Therapeutics, Top Alliance BioScience, Trethera, Xilio Therapeutics, Zenshine; Non-Financial Interests, Personal and Institutional, Principal Investigator: Adagene; Financial Interests, Personal and Institutional, Local PI: Allarity, Aptevo, Aulos, CUE BioPharma, EMD Serono, Gi Innovation, Harbour BioMed, IconOVir Bio, IGM Biosciences, MedKine, Moderna Tx, Peel Therapeutics, Phanes Therapeutics, Pieris Pharmaceuticals, Qurgen, RiboScience, Simcere, SK Life Sciences; Non-Financial Interests, Institutional, Funding: MT Group; Non-Financial Interests, Personal and Institutional, Funding: Nuvation, Preision for Medicine, Replimmune, Sairopa, Revolution Medicine, SK Life Sciences, Stemcell Technologies, Xilis; Financial Interests, Personal and Institutional, Funding: Pioma, Wugen Funding. N. Khaskhely, L. Bonham, C. Taromino, D. Taylor, J. Kumer: D. Huebner, M. Nelson: Financial Interests, Institutional, Full or part-time Employment: Aptevo Therapeutics; Financial Interests, Institutional, Stocks/Shares: Aptevo Therapeutics. P. Ellmark, S.V. Ambarkhane: Financial Interests, Personal, Full or part-time Employment: Alligator Bioscience; Financial Interests, Personal, Stocks/Shares: Alligator Bioscience. S. Fritzell: Financial Interests, Personal, Full or part-time Employment: Alligator Bioscience AB; Financial Interests, Personal, Stocks/Shares: Alligator Bioscience AB; Non-Financial Interests, Project Lead: Alligator Bioscience AB. A. Alahmadi: Financial Interests, Institutional, Research Grant: NCCN-AstraZeneca; Financial Interests, Institutional, Local PI: Genentech, Glided, Tempus; Non-Financial Interests, Advisory Role: Tempus; Non-Financial Interests, Principal Investigator: Aptevo, Lilly Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01